A5058700958- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Gallbladder and Bile Duct Disorders
- Colorectal Cancer Treatments and Studies
- Hepatitis B Virus Studies
- Pancreatitis Pathology and Treatment
- Renal cell carcinoma treatment
- Peptidase Inhibition and Analysis
- Axon Guidance and Neuronal Signaling
- Ferroptosis and cancer prognosis
- Cancer, Hypoxia, and Metabolism
- Apelin-related biomedical research
- Metastasis and carcinoma case studies
- Gastrointestinal Tumor Research and Treatment
- Sarcoma Diagnosis and Treatment
- Liver Diseases and Immunity
- Nanoparticle-Based Drug Delivery
- Colorectal and Anal Carcinomas
- Hepatitis C virus research
- Gut microbiota and health
National Health Research Institutes
2019-2025
National Cheng Kung University Hospital
2019-2025
Kaohsiung Medical University
2015-2024
Center for Cancer Research
2024
Kaohsiung Medical University Chung-Ho Memorial Hospital
2015-2024
National Cheng Kung University
2019-2023
Taipei Veterans General Hospital
2023
National Yang Ming Chiao Tung University
2023
PURPOSE Durable partial response (PR) and durable stable disease (SD) are often seen in patients with hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab (atezo-bev). This study investigates the outcome of these histopathology residual tumors. PATIENTS AND METHODS The IMbrave150 study's atezo-bev group was analyzed. PR or SD per RECIST v1.1 lasting more than 6 months defined as durable. For histologic analysis, a comparable real-world from Japan Taiwan who had undergone...
Oncogenic KRAS mutations are present in approximately 90% of pancreatic ductal adenocarcinoma (PDAC). However, Kras mutation alone is insufficient to transform precancerous cells into metastatic PDAC. This study investigates how KRAS-mutated epithelial acquire the capacity escape senescence or even immune clearance, thereby progressing advanced Single-cell RNA sequencing and analysis primary PDAC tumors were conducted. Genetically engineered pancreas-specific Kras-mutated, dual specificity...
633 Background: Immune checkpoint inhibitors (ICI) administered prior to liver resection (LR) lead pathological responses in patients with hepatocellular carcinoma (HCC). However, the relative value of versus radiological response predicting relapse-free survival (RFS) remains unclear. Methods: We pooled patient-level data from 111 (pts) HCC receiving ICI LR as part 5 phase I/II trials and observational clinical studies conducted 12 centres United States, Kingdom Asia, an academic consortium...
Abstract Background Cancer susceptibility germline mutations are associated with pancreatic ductal adenocarcinoma (PDAC). However, the hereditary status of PDAC and its impact on survival is largely unknown in Asian population. Methods Exome sequencing was performed 527 blood samples from individuals analyzed for 80 oncogenic genes. Pathogenic likely pathogenic (P/LP) variants were diagnosed according to ACMG variant classification categories. The association between homologous recombination...
Upfront resection (UR) followed by adjuvant chemotherapy remains the standard treatment for resectable pancreatic cancer. There is increasing evidence suggesting favourable outcomes toward neoadjuvant (NAC) surgery.All clinical staging with cancer patients treated at a tertiary medical centre from 2013 to 2020 were identified. The baseline characteristics, course, surgery outcome and survival results of UR or NAC compared.Finally, in 159 patients, 46 (29%) underwent 113 (71%) received UR. In...
Abstract Liposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI + 5-FU/LV) has shown to provide survival benefits for patients with gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma (PDAC) in NAPOLI-1 trial, which Asian experienced more hematological toxicity and subsequent dose modification. A retrospective chart review investigate the administration pattern, therapeutic efficacy safety profile of nal-IRI 5-FU/LV 44 consecutive advanced PDAC treated between December...
Abstract Advancement in systemic therapy, particularly immune checkpoint inhibitor (ICI)-based combination regimens, has transformed the treatment landscape for patients with advanced hepatocellular carcinoma (HCC). The advancement therapy also provides new opportunities of reducing recurrence after curative through adjuvant or improving resectability neoadjuvant therapy. Improved recurrence-free survival by ICI-based been reported other cancer types. In this article, developments and...
Semaphorins (SEMAs) are axon guidance factors that participate in axonal connections and nerve system development. However, the functional roles of SEMAs tumorigenesis still largely uncovered. By using silico data analysis, we found SEMA6C was downregulated pancreatic cancer, its reduction correlated with worse survival rates. RNA sequencing revealed cell cycle-related genes, especially cyclin D1, were significantly altered after blockage by neutralizing antibodies or ectopic expressions...
The nomogram derived from the pivotal phase III NAPOLI-1 study demonstrated a significant ability to predict median overall survival (OS) in gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma (PDAC) treated with liposomal irinotecan plus fluorouracil and leucovorin (nal-IRI+5-FU/LV). However, has not been validated real-world setting therefore applicability of daily practice remains unknown. This aims evaluate multicenter cohort.The was applied previously established cohort...
506 Background: Neoadjuvant use of immune checkpoint inhibitors (ICI) is feasible and achieves pathological responses in a subset patients with hepatocellular carcinoma (HCC). However, it not clear whether response to ICI translates into long-term survival benefit. Methods: We analysed patient-level data from 86 subjects recruited 4 prospective phase I/II clinical trials prior liver resection (LR) 9 centres the United States, Europe, Asia included cohort 23 (pts) receiving neoadjuvant off...
Burkitt lymphoma is characterized by high cell turnover and numerous cytoplasmic vacuoles that are demonstrated to be lipid droplets (LDs) decorated adipophilin. By contrast, variably observed in diffuse large B-cell (DLBCL) less well characterized. In this study, we first validated DLBCL indeed LDs Oil-red-O stain, Bodipy fluorescent electron microscopy. Second, a cohort of patients (n=52) showed effusional cells were associated with poorer prognosis ( P =0.029, log-rank test) higher...
Abstract Purpose: Modified gemcitabine and S-1 (GS) is an active regimen for patients with advanced biliary tract cancer (ABTC) in our previous study. Herein, we report the results of a single-arm phase II nivolumab plus modified GS (NGS) as first-line treatment ABTC. Patients Methods: received 240 mg 800 mg/m2 on day 1 daily 80/100/120 (based body surface area) days to 10, 2-week cycle. The primary endpoint was objective response rate (ORR). correlation between therapeutic efficacy genetic...
Background/Aims: A high-quality sample allows for next-generation sequencing and the administration of more tailored precision medicine treatments.We aimed to evaluate whether heparinized wet suction can obtain higher quality samples than standard dry-suction method during endoscopic ultrasound (EUS)-guided biopsy pancreatic masses. Methods:A prospective randomized crossover study was conducted.Patients with a solid mass were randomly allocated receive either first or dry first.For each...
The majority of gastrointestinal stromal tumors (GISTs) arise in the stomach and small intestine; primary GIST liver is extremely rare. GISTs share specific immunohistological features with melanoma, therefore, determining a definitive diagnosis can be difficult. However, electron microscopy used to aid differential GIST. present study reports first case KIT/platelet-derived growth factor receptor α (PDGFRA) wild-type, arising from long-term survivor anorectal melanoma. patient underwent APR...
Introduction: The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses immunotherapy remain poorly characterized. Methods: Patients HCC received immune checkpoint inhibitor (ICI)-based were retrospectively included. A response was defined as partial (PR) or stable disease (SD) per RECIST 1.1 for more than 8 months after initiation immunotherapy. Oligoprogression polyprogression at ≤3 >3 lesions,...
Background: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is currently the standard second-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC) after previous failed gemcitabine-based therapy. This population-based study aimed to evaluate efficacy safety of nal-IRI + 5-FU/LV association pre-emptive dosing outcomes in PDAC. Methods: We retrospectively enrolled a total 667 consecutive PDAC who received between August 2018 November 2020 at 9...
This multicenter, real-world cohort study aimed to evaluate the effectiveness of early cumulative dose administration and dosing pattern liposomal irinotecan plus fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma (mPDAC).The electronic medical records mPDAC treated nal-IRI+5-FU/LV nine participating centers were manually reviewed. To accommodate NAPOLI-1 population, only an Eastern Cooperative Oncology Group...
Abstract Background & Aims Gemcitabine plus cisplatin (GC) remains the standard, frontline therapy for advanced biliary tract cancer (ABTC). The JCOG1113 study suggested that gemcitabine S‐1 (GS) had noninferior median overall survival and comparable incidence of significant neutropenia as compared to GC treatments. This evaluates efficacy safety a modified GS regimen. Methods eligible patients with chemonaive, measurable ABTC received 800 mg/m 2 on day 1 80 /day (80/100/120 mg body...